<?xml version='1.0' encoding='utf-8'?>
<document id="25559065"><sentence text="Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects."><entity charOffset="40-50" id="DDI-PubMed.25559065.s1.e0" text="paroxetine" /><entity charOffset="55-68" id="DDI-PubMed.25559065.s1.e1" text="roxithromycin" /><entity charOffset="72-95" id="DDI-PubMed.25559065.s1.e2" text="bencycloquidium bromide" /><pair ddi="false" e1="DDI-PubMed.25559065.s1.e0" e2="DDI-PubMed.25559065.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25559065.s1.e0" e2="DDI-PubMed.25559065.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s1.e0" e2="DDI-PubMed.25559065.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25559065.s1.e1" e2="DDI-PubMed.25559065.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s1.e1" e2="DDI-PubMed.25559065.s1.e2" /></sentence><sentence text="The aim of this study was to investigate the potential drug-drug interaction between Bencycloquidium bromide (BCQB) and paroxetine, and between BCQB and roxithromycin"><entity charOffset="85-108" id="DDI-PubMed.25559065.s2.e0" text="Bencycloquidium bromide" /><entity charOffset="110-114" id="DDI-PubMed.25559065.s2.e1" text="BCQB" /><entity charOffset="120-130" id="DDI-PubMed.25559065.s2.e2" text="paroxetine" /><entity charOffset="144-148" id="DDI-PubMed.25559065.s2.e3" text="BCQB" /><entity charOffset="153-166" id="DDI-PubMed.25559065.s2.e4" text="roxithromycin" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e0" e2="DDI-PubMed.25559065.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e0" e2="DDI-PubMed.25559065.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e0" e2="DDI-PubMed.25559065.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e0" e2="DDI-PubMed.25559065.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e0" e2="DDI-PubMed.25559065.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e1" e2="DDI-PubMed.25559065.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e1" e2="DDI-PubMed.25559065.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e1" e2="DDI-PubMed.25559065.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e1" e2="DDI-PubMed.25559065.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e2" e2="DDI-PubMed.25559065.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e2" e2="DDI-PubMed.25559065.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e2" e2="DDI-PubMed.25559065.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e3" e2="DDI-PubMed.25559065.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25559065.s2.e3" e2="DDI-PubMed.25559065.s2.e4" /></sentence><sentence text="" /><sentence text="Two studies were conducted on healthy male Chinese volunteers" /><sentence text=" Study A was an open-label, two-period, one-sequence crossover study (n=21)" /><sentence text=" Each participant received a single nasal spray dose of BCQB 180μg on day 1"><entity charOffset="56-68" id="DDI-PubMed.25559065.s6.e0" text="BCQB" /></sentence><sentence text=" After a 7-day wash-out period, subjects received 20mg of paroxetine from day 8 to 17, and were co-administered 20mg of paroxetine and BCQB 180μg on day 18"><entity charOffset="58-68" id="DDI-PubMed.25559065.s7.e0" text="paroxetine" /><entity charOffset="120-130" id="DDI-PubMed.25559065.s7.e1" text="paroxetine" /><entity charOffset="135-139" id="DDI-PubMed.25559065.s7.e2" text="BCQB" /><pair ddi="false" e1="DDI-PubMed.25559065.s7.e0" e2="DDI-PubMed.25559065.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25559065.s7.e0" e2="DDI-PubMed.25559065.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s7.e0" e2="DDI-PubMed.25559065.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25559065.s7.e1" e2="DDI-PubMed.25559065.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s7.e1" e2="DDI-PubMed.25559065.s7.e2" /></sentence><sentence text=" In study B, participants (n=12) were randomly assigned to two groups" /><sentence text=" In period I, group A received BCQB 180μg on day 1, followed by the same dose four times daily from day 4 to 10, then, on day 11 a single dose of 150mg roxithromycin with BCQB 180μg were co-administered"><entity charOffset="152-165" id="DDI-PubMed.25559065.s9.e0" text="roxithromycin" /><entity charOffset="31-43" id="DDI-PubMed.25559065.s9.e1" text="BCQB" /><entity charOffset="171-183" id="DDI-PubMed.25559065.s9.e2" text="BCQB" /><pair ddi="false" e1="DDI-PubMed.25559065.s9.e1" e2="DDI-PubMed.25559065.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s9.e1" e2="DDI-PubMed.25559065.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25559065.s9.e1" e2="DDI-PubMed.25559065.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25559065.s9.e0" e2="DDI-PubMed.25559065.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25559065.s9.e0" e2="DDI-PubMed.25559065.s9.e2" /></sentence><sentence text=" In parallel, group B received a single dose of roxithromycin 150mg on day 1, followed by 300mg of roxithromycin from day 4 to 10, then, on day 11 a single dose of BCQB 180μg with roxithromycin 300mg were co-administered"><entity charOffset="48-61" id="DDI-PubMed.25559065.s10.e0" text="roxithromycin" /><entity charOffset="99-112" id="DDI-PubMed.25559065.s10.e1" text="roxithromycin" /><entity charOffset="180-193" id="DDI-PubMed.25559065.s10.e2" text="roxithromycin" /><entity charOffset="164-176" id="DDI-PubMed.25559065.s10.e3" text="BCQB" /><pair ddi="false" e1="DDI-PubMed.25559065.s10.e0" e2="DDI-PubMed.25559065.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25559065.s10.e0" e2="DDI-PubMed.25559065.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s10.e0" e2="DDI-PubMed.25559065.s10.e3" /><pair ddi="false" e1="DDI-PubMed.25559065.s10.e0" e2="DDI-PubMed.25559065.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25559065.s10.e1" e2="DDI-PubMed.25559065.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s10.e1" e2="DDI-PubMed.25559065.s10.e3" /><pair ddi="false" e1="DDI-PubMed.25559065.s10.e1" e2="DDI-PubMed.25559065.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25559065.s10.e3" e2="DDI-PubMed.25559065.s10.e3" /><pair ddi="false" e1="DDI-PubMed.25559065.s10.e3" e2="DDI-PubMed.25559065.s10.e2" /></sentence><sentence text=" After a wash-out time of 7days the respective treatments of each group (A and B) were swapped in period II" /><sentence text=" Blood samples were collected for pharmacokinetic analysis" /><sentence text=" Statistical comparison of pharmacokinetic parameters was performed to identify a possible drug interaction between treatments" /><sentence text=" Tolerability was evaluated by recording adverse events" /><sentence text="" /><sentence text="Study A: Geometric mean AUC0-36 for BCQB alone and co-administered with paroxetine were 474"><entity charOffset="72-82" id="DDI-PubMed.25559065.s16.e0" text="paroxetine" /><entity charOffset="36-45" id="DDI-PubMed.25559065.s16.e1" text="BCQB" /><pair ddi="false" e1="DDI-PubMed.25559065.s16.e1" e2="DDI-PubMed.25559065.s16.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s16.e1" e2="DDI-PubMed.25559065.s16.e0" /></sentence><sentence text="3 and 631" /><sentence text="3pgh/ml, respectively" /><sentence text=" The geometric mean ratio (GMR) of AUC0-36 was 1" /><sentence text="33 (1" /><sentence text="13-1" /><sentence text="46), 90% C" /><sentence text="Is, and was out the predefined bioequivalence interval (90% C" /><sentence text="Is, 0" /><sentence text="80-1" /><sentence text="25)" /><sentence text=" Geometric mean Cmax were 187" /><sentence text="0 and 181" /><sentence text="2pg/ml" /><sentence text=" Study B: The GMR of AUC0-36 was 0" /><sentence text="98 (0" /><sentence text="90-1" /><sentence text="07), 90% C" /><sentence text="Is for BCQB, and the GMR of AUC0-72 was 0"><entity charOffset="7-10" id="DDI-PubMed.25559065.s34.e0" text="BCQB" /></sentence><sentence text="98 (0" /><sentence text="87-1" /><sentence text="11), 90% C" /><sentence text="Is for roxithromycin"><entity charOffset="7-20" id="DDI-PubMed.25559065.s38.e0" text="roxithromycin" /></sentence><sentence text=" Both GMRs were within the predefined bioequivalence interval (90% C" /><sentence text="Is, 0" /><sentence text="80-1" /><sentence text="25)" /><sentence text=" Other pharmacokinetic parameters were within the predefined interval" /><sentence text=" No serious adverse events were reported and no significant clinical changes were observed in laboratory test results, vital signs and ECGs in any of the studies" /><sentence text=" All treatments were well tolerated" /><sentence text="" /><sentence text="The co-administration of BCQB with paroxetine showed a moderate increase in BCQB exposure, but was not clinically relevant"><entity charOffset="35-45" id="DDI-PubMed.25559065.s47.e0" text="paroxetine" /><entity charOffset="25-34" id="DDI-PubMed.25559065.s47.e1" text="BCQB" /><entity charOffset="76-85" id="DDI-PubMed.25559065.s47.e2" text="BCQB" /><pair ddi="false" e1="DDI-PubMed.25559065.s47.e1" e2="DDI-PubMed.25559065.s47.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s47.e1" e2="DDI-PubMed.25559065.s47.e0" /><pair ddi="false" e1="DDI-PubMed.25559065.s47.e1" e2="DDI-PubMed.25559065.s47.e2" /><pair ddi="false" e1="DDI-PubMed.25559065.s47.e0" e2="DDI-PubMed.25559065.s47.e0" /><pair ddi="false" e1="DDI-PubMed.25559065.s47.e0" e2="DDI-PubMed.25559065.s47.e2" /></sentence><sentence text=" Also, no drug interaction was found between BCQB and roxithromycin"><entity charOffset="54-67" id="DDI-PubMed.25559065.s48.e0" text="roxithromycin" /><entity charOffset="45-57" id="DDI-PubMed.25559065.s48.e1" text="BCQB" /><pair ddi="false" e1="DDI-PubMed.25559065.s48.e1" e2="DDI-PubMed.25559065.s48.e1" /><pair ddi="false" e1="DDI-PubMed.25559065.s48.e1" e2="DDI-PubMed.25559065.s48.e0" /></sentence><sentence text="" /></document>